Amgen anunta achizitia anului in sectorul medical - 14 decembrie 2022: Diferență între versiuni

<p>Amgen [https://www.wsj.com/articles/amgen-in-advanced-talks-to-buy-horizon-therapeutics-11670785882 va achizitiona] Horizon Therapeutics pentru 28 mld. USD in cel mai mare deal farma din acest an. Pentru compania irlandeza lider in aria medicatiei destinate bolilor autoimune au mai licitat Sanofi si Johnson &amp; Johnson.</p><p>In 2021, Tepezza, cel mai important medicament produs de Horizon Therapeutics, [https://www.wsj.com/articles/amgen-in-advanced-talks-to-buy-horizon-therapeutics-11670785882#:~:text=Last%20year%2C%20revenue%20from%20Tepezza%20more%20than%20doubled%2C%20driving%20Horizon%E2%80%99s%20overall%20net%20sales%2047%25%20higher%20to%20%243.23%20billion.%20Horizon%20has%20said%20that%20annual%20global%20net%20sales%20of%20the%20drug%20are%20targeted%20to%20eventually%20peak%20at%20more%20than%20%244%20billion%20as%20the%20company%20aims%20to%20win%20approval%20to%20sell%20it%20in%20Europe%20and%20Japan. a inregistrat] exclusiv in SUA vanzari de 2x mai mari decat anul precedent. Tepezza [https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease este] singurul medicament autorizat in SUA pentru tratarea bolii ochiului tiroidian, dar Horizon Therapeutics vrea sa obtina permisiunea comercializarii in Europa si Japonia. Veniturile totale ale companiei au crescut anul trecut cu 47%, la peste 3 mld. USD.</p><p>Trimestrul trecut, Amgen [https://www.reuters.com/business/healthcare-pharmaceuticals/amgen-posts-higher-third-quarter-revenue-profit-2022-11-03/ a avut] venituri totale de 6.7 mld. USD, nu mai putin de 11 produse ale companiei realizand incasari record.</p><p>Amgen este listata la NASDAQ si inclusa in structura indicelui Dow Jones Industrial Average. Actiunile s-au apreciat cu 20% in acest an si cu 53% in ultimii 5 ani, valoarea de piata a companiei fiind de 145 mld. USD.</p><p>(US.AMGN)</p>